In search of druggable targets for GBM amino acid metabolism

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Panosyan, Eduard H ^a   Lin, Henry J ^a   Koster, Jan ^b   Lasky, Joseph L ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Amino acid (AA) metabolism; Asparagine (Asn); BCAT1 (branched chain amino acid transaminase 1); Glioblastoma (GBM); Glutamine (Gln)

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; ARGININE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINATE SYNTHASE 1; ASPARAGINE; ASPARTATE AMINOTRANSFERASE ISOENZYME 1; ASPARTOACYLASE; BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE; BRANCHED CHAIN AMINO ACID TRANSFERASE 1; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GLUTAMATE DECARBOXYLASE 2; GLUTAMIC ACID; GLUTATHIONE SYNTHASE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; PROLINE DEHYDROGENASE; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; AMINO ACID; UREA;

AMINO ACID METABOLISM; ARTICLE; BRAIN TISSUE; CANCER GRADING; CANCER SURVIVAL; CHILDHOOD CANCER; DATA BASE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; MESENCHYMOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL PREDICTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UREA CYCLE; BRAIN TUMOR; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETICS; METABOLISM; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

AMINO ACIDS; BRAIN NEOPLASMS; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUTAMIC ACID; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PROGNOSIS; SURVIVAL ANALYSIS; UREA;

EID: 85014115242     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3148-1     Document Type: Article

References (39)

1. Squatrito M, Holland EC. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res. 2011;71(18):5945-9.
2. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncology. 2010;12(6):603-7.
3. Mellinghoff IK, Lassman AB, Wen PY. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia. 2011;59(8):1205-12.
4. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro-Oncology. 2014;16(11):1441-58.
5. Weber JS. Current perspectives on immunotherapy. Semin Oncol. 2014;41(Supplement 5):S14-29.
6. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10(9):671-84.
7. Sciacovelli M, Gaude E, Hilvo M, Frezza C. Chapter One - The Metabolic Alterations of Cancer Cells. In: Lorenzo G, Guido K, editors. Methods in Enzymology. Volume 542, edn. USA: Academic Press; 2014. p. 1-23.
8. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367-93.
9. Bertino JR. Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol. 2009;22(4):577-82.
10. Maxwell MB, Maher KE. Chemotherapy-induced myelosuppression. Semin Oncol Nurs. 1992;8(2):113-23.
11. Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 2012;9(7):2444-53.
12. Turkalp Z, Karamchandani J, Das S. Idh mutation in glioma: New insights and promises for the future. JAMA Neurol. 2014;71(10):1319-25.
13. Seyfried TN, Flores R, Poff AM, D'Agostino DP, Mukherjee P. Metabolic therapy: A new paradigm for managing malignant brain cancer. Cancer Lett. 2015;356(2, Part A):289-300.
14. Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2013;2(3):289-99.
15. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T, et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med. 2012;1(11):811-24.
16. Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus R-I, et al. Comparison of the amino acid tracers 18 F-FET and 18 F-DOPA in high-grade glioma patients. J Nucl Med. 2014;55(10):1611-6.
17. Langen K-J, Tatsch K, Grosu A-L, Jacobs AH, Weckesser M, Sabri O. Diagnostics of cerebral gliomas with radiolabeled amino acids. Dtsch Arztebl Int. 2008;105(4):55-61.
18. Bender DA. Amino Acids Synthesized from Glutamate: Glutamine, Proline, Ornithine, Citrulline and Arginine. In: Amino Acid Metabolism. Chichester: Wiley; 2012. p. 157-223.
19. R2: Genomics Analysis and Visualization Platform. http://r2.amc.nl. Accessed 5 Jan 2016.
20. The Human Protein Atlas. http://www.proteinatlas.org/cancer. Accessed 5 Jan 2016.
21. Lu J, Cowperthwaite MC, Burnett MG, Shpak M. Molecular predictors of long-term survival in glioblastoma multiforme patients. PLoS ONE. 2016;11(4):e0154313.
22. Bush NAO, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev. 2016;1-14.
23. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AHC, Karra D, Piro RM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 2013;19(7):901-8.
24. Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel A, Abi-Habib R. Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. J Neurooncol. 2015;122(1):75-85.
25. Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeyer B, Linnebacher M, Maletzki C. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol Ther. 2015;16(7):1047-55.
26. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, et al. Phase II study of Pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol. 2010;28(13):2220-6.
27. Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004;10(16):5335-41.
28. Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR. Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg. 2013;119(2):427-33.
29. D'Souza MM, Sharma R, Jaimini A, Panwar P, Saw S, Kaur P, Mondal A, Mishra A, Tripathi RP. 11C-MET PET/CT and Advanced MRI in the Evaluation of Tumor Recurrence in High-Grade Gliomas. Clin Nucl Med. 2014;39(9):791-8.
30. Palanichamy K, Thirumoorthy K, Kanji S, Gordon N, Singh R, Jacob JR, Sebastian N, Litzenberg KT, Patel D, Bassett E, et al. Methionine and kynurenine activate oncogenic kinases in glioblastoma, and methionine deprivation compromises proliferation. Clin Cancer Res. 2016;22(14):3513-23.
31. Long PM, Tighe SW, Driscoll HE, Fortner KA, Viapiano MS, Jaworski DM. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. J Cell Physiol. 2015;230(8):1929-43.
32. Frisell WR, Mackenzie CG. The binding sites of sarcosine oxidase. J Biol Chem. 1955;217(1):275-86.
33. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 2015;125(4):1591-602.
34. Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy TF, Nghiemphu PL. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. J Neurooncol. 2016;128:57-66.
35. Park S, Ahn ES, Han DW, Lee JH, Min KT, Kim H, Hong Y-W. Pregabalin and gabapentin inhibit substance P-induced NF-ΚB activation in neuroblastoma and glioma cells. J Cell Biochem. 2008;105(2):414-23.
36. Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, et al. Pilot study of intravenous melphalan combined with continuous infusion L-S, R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer. 2015;62(10):1739-46.
37. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-15.
38. Platten M, von Knebel DN, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 2015;5:673.
39. Wolf A, Agnihotri S, Guha A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget. 2010;1:552-62.